M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn Pharmaceutical Technologyargenx has entered into a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value.Immunology & InflammationRead full story pharminent July 28, 2026 (Last updated: July 28, 2026) Pharmaceutical Technology argenx has entered into a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value. Immunology & Inflammation Read full story Post navigation Previous: AstraZeneca Says Drug Pricing Is ‘Evolving’ in Response to Trump’s Most-Favored-Nation PolicyNext: GSK to quit Stevenage for new R&D site in Cambridge Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026